戻る Agenda
Session 2 Track 2: Extrahepatic Delivery 1: Engineering LNPs and Ligand Conjugates for Oligonucleotide Delivery to the Kidney and Lung Tumors
Session Chair(s)
Jeffrey Foy, PhD
Executive Director, Toxicology, Nimbus Therapeutics, United States
Elena Braithwaite, PhD
Toxicologist, FDA, United States
Development of safe and efficacious oligonucleotide-based therapeutics (ONTs) can be facilitated by optimized delivery. Therefore, ONT delivery systems are an active area of research, as they can direct ONTs to specific genes or tissues to improve overall drug safety and therapeutic efficacy. This session will feature advances in targeted ONT delivery using ligands or lipid nanoparticles (LNPs). Together, these presentations reflect the field's growing emphasis on precision delivery, therapeutic efficacy, and safety.
Development of Ligand-targeted Chimeric siRNAs for the Treatment of KRAS-mediated Solid Tumors
Michael Dombeck EnFuego Therapeutics
LNP Delivery in the Kidney
Ronen Eavri, Barcode Nanotech
siRNA-ligand Conjugates for Delivery to the Kidney
Alfica Sehgal, Judo Bio
Learning Objective : At the conclusion of this session, participants should be able to: - Define ligand-mediated proximal tubule cell delivery within a complex renal environment
- Describe the scientific rationale for using a multi-component ONT delivery system including a targeting ligand, a primary therapeutic target, and a secondary therapeutic target
- Explain how AI can aid in the screening and optimization of LNP-based specific organ targeting of ONTs
Speaker(s)
Development of Ligand-targeted Chimeric siRNAs for the Treatment of KRAS-mediated Solid Tumors
Michael Dombeck, MBA
CEO, EnFuego Therapeutics, United States
Molecular Barcoding Approaches for RNA Therapeutics Delivery
Ronen Eavri, PhD, MBA
CEO and Co-Founder, Barcode Nanotech, Israel
siRNA-ligand Conjugates for d=Delivery to the Kidney
Alfica Sehgal, PhD
CSO, Judo Bio, United States